EE04481B1 - Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks - Google Patents

Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks

Info

Publication number
EE04481B1
EE04481B1 EE9800255A EE9800255A EE04481B1 EE 04481 B1 EE04481 B1 EE 04481B1 EE 9800255 A EE9800255 A EE 9800255A EE 9800255 A EE9800255 A EE 9800255A EE 04481 B1 EE04481 B1 EE 04481B1
Authority
EE
Estonia
Prior art keywords
peptide
pharmaceutical composition
immune modulation
based pharmaceutical
adjuvant based
Prior art date
Application number
EE9800255A
Other languages
English (en)
Estonian (et)
Other versions
EE9800255A (et
Inventor
Schmidt Walter
L. Birnstiel Max
Steinlein Peter
Buschle Michael
Schweighoffer Tam�s
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04481(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800255A publication Critical patent/EE9800255A/xx
Publication of EE04481B1 publication Critical patent/EE04481B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EE9800255A 1996-02-24 1997-02-21 Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks EE04481B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (2)

Publication Number Publication Date
EE9800255A EE9800255A (et) 1999-02-15
EE04481B1 true EE04481B1 (et) 2005-06-15

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800255A EE04481B1 (et) 1996-02-24 1997-02-21 Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks

Country Status (34)

Country Link
US (1) US7105162B1 (sr)
EP (1) EP0881906B2 (sr)
JP (1) JP4184433B2 (sr)
KR (1) KR100457647B1 (sr)
CN (1) CN1177610C (sr)
AR (1) AR005945A1 (sr)
AT (1) ATE274350T1 (sr)
AU (1) AU722264B2 (sr)
BG (1) BG63682B1 (sr)
BR (1) BR9707694A (sr)
CA (1) CA2243559C (sr)
CO (1) CO4600681A1 (sr)
CZ (1) CZ295396B6 (sr)
DE (1) DE59711873D1 (sr)
DK (1) DK0881906T4 (sr)
EE (1) EE04481B1 (sr)
ES (1) ES2225951T5 (sr)
HR (1) HRP970100B1 (sr)
HU (1) HU224410B1 (sr)
ID (1) ID16038A (sr)
IL (1) IL125361A (sr)
MY (1) MY119276A (sr)
NO (1) NO983850L (sr)
NZ (1) NZ332020A (sr)
PE (1) PE55398A1 (sr)
PL (1) PL189413B1 (sr)
PT (1) PT881906E (sr)
RO (1) RO119344B1 (sr)
RS (1) RS50101B (sr)
SI (1) SI0881906T2 (sr)
SK (1) SK284582B6 (sr)
TR (1) TR199801649T2 (sr)
TW (1) TW585774B (sr)
WO (1) WO1997030721A1 (sr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
JP4875799B2 (ja) * 1998-02-25 2012-02-15 アメリカ合衆国 Ａｄｐ−リボシル化外毒素により誘引される経皮免疫応答を促進するための皮膚浸透性エンハンサーおよびバリア崩壊剤の使用
JP4540845B2 (ja) * 1998-04-20 2010-09-08 トーレイ パインズ インスティテュート フォー モレキュラー スタディーズ ランゲルハンス細胞遊走を誘導する局所的免疫刺激
EP2204186B1 (en) * 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
CA2433794A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
EP2287315A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
EP2182065A3 (en) 2003-03-31 2010-09-15 Intercell AG Staphylococcus epidermidis antigens
EP2336357A1 (en) 2003-04-15 2011-06-22 Intercell AG S. pneumoniae antigens
CA2522986A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens i + ii
AU2004242842B2 (en) 2003-05-30 2011-11-03 Intercell Ag Enterococcus antigens
AU2004255456B2 (en) 2003-07-11 2010-06-24 Intercell Ag HCV vaccines
DE602005004014T2 (de) 2004-03-12 2008-12-11 Intercell Ag Verfahren zur solubilisierung von peptid-mischungen
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE465173T1 (de) 2004-09-24 2010-05-15 Intercell Ag Verändertes vp-1capsidprotein von parvovirus b19
JP2008517973A (ja) * 2004-10-29 2008-05-29 インターツェル・アクチェンゲゼルシャフト 慢性ｈｃｖ患者へのｈｃｖワクチン
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
AU2008248755A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
JP2010530229A (ja) 2007-06-18 2010-09-09 インターセル アーゲー クラミジア属の抗原
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
CA2719059C (en) * 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
JP2013503148A (ja) * 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
EP3392291B1 (en) * 2015-12-16 2020-08-05 Huvet Bio, Inc. Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene
EP3431595A4 (en) 2016-03-15 2019-11-20 Repertoire Genesis Incorporation MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
US20200282032A1 (en) * 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
ES2972560T3 (es) 2016-10-11 2024-06-13 Nec Corp Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (sr) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
IL82841A (en) * 1986-06-13 1992-11-15 Oncogen Ligands and in vitro methods for augmenting b-cell proliferation
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5480967A (en) 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
PT636028E (pt) 1992-04-03 2004-07-30 Univ California Sistema de fornecimento de polinucleotidos auto-organizado
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) * 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
AU1875997A (en) 1997-09-10
US7105162B1 (en) 2006-09-12
HK1017257A1 (en) 1999-11-19
CN1211926A (zh) 1999-03-24
TR199801649T2 (xx) 1998-12-21
KR100457647B1 (ko) 2005-06-20
ID16038A (id) 1997-08-28
HUP9901186A2 (hu) 1999-07-28
SK114598A3 (en) 1999-06-11
KR19990082601A (ko) 1999-11-25
HU224410B1 (hu) 2005-08-29
HUP9901186A3 (en) 2001-01-29
MY119276A (en) 2005-04-30
RO119344B1 (ro) 2004-08-30
EE9800255A (et) 1999-02-15
SI0881906T2 (sl) 2009-06-30
EP0881906A1 (de) 1998-12-09
ES2225951T3 (es) 2005-03-16
NO983850D0 (no) 1998-08-21
DK0881906T3 (da) 2004-12-20
SK284582B6 (sk) 2005-07-01
PL189413B1 (pl) 2005-08-31
RS50101B (sr) 2009-01-22
JP4184433B2 (ja) 2008-11-19
PT881906E (pt) 2004-10-29
IL125361A0 (en) 1999-03-12
SI0881906T1 (en) 2004-12-31
CO4600681A1 (es) 1998-05-08
PE55398A1 (es) 1998-09-22
EP0881906B1 (de) 2004-08-25
IL125361A (en) 2002-08-14
DE59711873D1 (de) 2004-09-30
WO1997030721A1 (de) 1997-08-28
DK0881906T4 (da) 2009-05-25
EP0881906B2 (de) 2009-02-04
CA2243559A1 (en) 1997-08-28
ES2225951T5 (es) 2009-06-15
BG63682B1 (bg) 2002-09-30
BG102714A (en) 1999-06-30
CZ268998A3 (cs) 1999-07-14
ATE274350T1 (de) 2004-09-15
HRP970100B1 (en) 2001-04-30
NZ332020A (en) 2000-02-28
AU722264B2 (en) 2000-07-27
CN1177610C (zh) 2004-12-01
AR005945A1 (es) 1999-07-21
NO983850L (no) 1998-10-21
CZ295396B6 (cs) 2005-08-17
HRP970100A2 (en) 1998-04-30
TW585774B (en) 2004-05-01
CA2243559C (en) 2011-08-09
BR9707694A (pt) 1999-07-27
YU6297A (sh) 1999-09-27
JP2000506125A (ja) 2000-05-23
PL328455A1 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
EE04481B1 (et) Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks
BR9607317A (pt) Peptídios e composição farmacêutica
IL129164A0 (en) Antibody against human parathormone related peptides
FI961350A7 (fi) Hapteenimerkityt peptidit
ID17860A (id) Komposisi vaksin
NO985680D0 (no) Peptidderivater
NO983849L (no) Peptidderivater
FI970168A0 (fi) Peptidejä
FI963334L (fi) Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö
EE03857B1 (et) Ravimkoostised külmkuivatamiseks
LV12250A (lv) Farmaceitiskas kompozicijas uz diklofenaka bazes
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
FI964363L (fi) Peptidejä
FI971427A7 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
ID18698A (id) Komposisi farmasi
GB2331521B (en) Vaccine preparations
ITMI962628A0 (it) Composizione farmaceutica
IL116976A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
IL112094A0 (en) Novel peptides and pharmaceutical compositions comprising them
SG54113A1 (en) Novel peptide a method for its preparation and a pharmaceutical composition containing the peptide
ZA96741B (en) Peptide a method for its preparation and a pharmaceutical composition containing the peptide
ITMI922675A1 (it) Peptidi immunogenici
SE9604299D0 (sv) Pharmaceutical composition
SE9601854D0 (sv) Farmaceutisk komposition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231